More than 2 in 5 American Adults have Prediabetes, but Prevention of Type 2 Diabetes is Within Reach

CDC and the Ad Council launched a nationwide English- and Spanish-language PSA campaign targeting the more than 115.2 million U.S. adults with prediabetes, over two in five of whom are largely unaware of their risk. The campaign directs audiences to a one-minute risk test and CDC’s National Diabetes Prevention Program; since 2016, the initiative has generated more than 30 million risk-test completions and nearly 330,000 program referrals. The public-health initiative is funded through donated media time and space, limiting direct financial-market implications.

Analysis

This is not a near-term earnings event: unpaid-media campaigns generally create diffuse, delayed behavior change rather than measurable demand in a single quarter. The investable transmission channel is higher screening and primary-care utilization, which modestly favors Quest Diagnostics (DGX), Labcorp (LH), and value-based-care operators before it affects diabetes drug volumes. For GLP-1 manufacturers Eli Lilly (LLY) and Novo Nordisk (NVO), greater identification of metabolic risk can expand the addressable-treatment funnel over 6-18 months, but only if physician follow-up converts into reimbursed pharmacotherapy rather than lifestyle-program participation alone.

The less obvious offset is that successful prevention is structurally negative at the margin for the future diabetes-treatment pool, including insulin and glucose-monitoring demand. That said, the addressable population is sufficiently large and progression rates sufficiently gradual that any prevention effect will be immaterial to LLY/NVO revenue forecasts over the next 1-3 years; obesity-label expansion, supply availability, and payer coverage remain dominant variables. Consensus may over-credit awareness campaigns as a GLP-1 catalyst: conversion requires confirmatory testing, clinician capacity, and coverage approval, each of which is a larger bottleneck than consumer awareness.

No directional trade is warranted on the release alone. The actionable signal would be a sustained increase in diabetes-screening volumes or National DPP/primary-care referrals over two reporting periods, which could precede modest utilization upside for DGX/LH and managed-care screening vendors. Thesis is falsified if utilization data remain flat, or if commercial payers tighten metabolic-drug prior authorization despite higher diagnosis rates.

Key Decisions for Investors

• No immediate position: treat this as a low-impact policy/awareness datapoint rather than a catalyst for LLY, NVO, DGX, or LH.
• Add DGX and LH to a 1-3 month utilization watchlist; consider a relative long only if quarterly test-volume growth or management commentary shows screening-driven acceleration above current guidance, with a stop on unchanged volumes and no guidance uplift.
• Do not chase LLY/NVO on the awareness narrative. Reassess long exposure only if diagnosis/referral data are accompanied by improving payer coverage or prescription growth; supply constraints and reimbursement remain the primary earnings sensitivities.
• For a 6-18 month structural monitor, track diabetes-prevention enrollment against new diabetes incidence. Material, sustained prevention uptake would be a modest long-duration headwind to legacy diabetes-device and insulin-volume assumptions, but is currently too small for a standalone short.